This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Accuray (ARAY) registered decline in Product and Service revenues in Q4
Accuray (ARAY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks
by Sriparna Ghosal
In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
Accuray's New CyberKnife S7 System to Boost Patient Care
by Zacks Equity Research
Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
Here's Why You Should Add Accuray to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.
Why Is Accuray (ARAY) Down 9.2% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
6 Stocks to Benefit From the 'New Normal'
by Zacks Equity Research
The coronavirus-led 'new normal' has altered several businesses. Here are three sectors that will see a boom in the near future.
Delivery Robots Making an Impression Amid Coronavirus Pandemic
by Zacks Equity Research
Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.
How Accuray (ARAY) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Accuray (ARAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Accuray (ARAY) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes Accuray (ARAY) a New Strong Buy Stock
by Zacks Equity Research
Accuray (ARAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for May 1st
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.
Accuray (ARAY) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 200.00% and 3.21%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Accuray in Your Portfolio
by Sriparna Ghosal
Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.
Why You Should Invest in Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
by Zacks Equity Research
Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.
Here's Why Investors Should Buy Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) sees a slew of developments lately.
Masimo & University Hospitals Unite for Patient Monitoring
by Zacks Equity Research
Masimo (MASI) sees a plethora of developments lately.
PRA Health's New Program to Lend Support to Healthcare System
by Zacks Equity Research
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.